Michel P Coleman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1888034/publications.pdf

Version: 2024-02-01

361 papers 34,828 citations

89 h-index 175 g-index

367 all docs

367 docs citations

367 times ranked

34651 citing authors

#	Article	IF	CITATIONS
1	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37â€^513â€^025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, The, 2018, 391, 1023-1075.	6.3	3,228
2	Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	6.3	1,863
3	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
4	An international association between Helicobacter pylori infection and gastric cancer. Lancet, The, 1993, 341, 1359-1363.	6.3	1,134
5	Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncology, The, 2008, 9, 730-756.	5.1	1,059
6	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the) Tj ETQq0 0 0 r Lancet, The, 2011, 377, 127-138.	gBT /Over 6.3	lock 10 Tf 50 999
7	EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. European Journal of Cancer, 2009, 45, 931-991.	1.3	740
8	The global burden of women's cancers: a grand challenge in global health. Lancet, The, 2017, 389, 847-860.	6.3	666
9	EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology, 2003, 14, v61-v118.	0.6	638
10	Cancer survival in <scp>C</scp> hina, 2003–2005: A populationâ€based study. International Journal of Cancer, 2015, 136, 1921-1930.	2.3	585
11	Rare cancers are not so rare: The rare cancer burden in Europe. European Journal of Cancer, 2011, 47, 2493-2511.	1.3	573
12	Origins of socio-economic inequalities in cancer survival: a review. Annals of Oncology, 2006, 17, 5-19.	0.6	550
13	Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. European Journal of Cancer, 2013, 49, 684-695.	1.3	519
14	Survival of European children and young adults with cancer diagnosed 1995–2002. European Journal of Cancer, 2009, 45, 992-1005.	1.3	442
15	Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax, 2013, 68, 551-564.	2.7	428
16	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 2003, 14, v128-v149.	0.6	400
17	Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group Gut, 1993, 34, 1672-1676.	6.1	382
18	Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer, 2004, 90, 1367-1373.	2.9	350

#	Article	IF	Citations
19	40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet, The, 2015, 385, 1206-1218.	6.3	345
20	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	1.3	344
21	Radiation Dose and Second Cancer Risk in Patients Treated for Cancer of the Cervix. Radiation Research, 1988, 116, 3.	0.7	343
22	Long-term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 1987, 94, 620-635.	1.1	284
23	Trends in Cancer Incidence, Survival and Mortality. , 2009, , 1-15.		270
24	Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registries. International Journal of Cancer, 1987, 39, 571-585.	2.3	256
25	Cohort Study Analysis with a FORTRAN Computer Program. International Journal of Epidemiology, 1986, 15, 134-137.	0.9	251
26	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	1.3	248
27	Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. International Journal of Cancer, 2003, 106, 416-422.	2.3	241
28	Excess mortality in England and Wales, and in Greater London, during the 1995 heatwave. Journal of Epidemiology and Community Health, 1998, 52, 482-486.	2.0	240
29	Continuing Rapid Increase in Esophageal Adenocarcinoma in England and Wales. American Journal of Gastroenterology, 2008, 103, 2694-2699.	0.2	239
30	Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut, 2011, 60, 806-813.	6.1	238
31	Childhood cancer burden: a review of global estimates. Lancet Oncology, The, 2019, 20, e42-e53.	5.1	237
32	The advantage of women in cancer survival: An analysis of EUROCARE-4 data. European Journal of Cancer, 2009, 45, 1017-1027.	1.3	233
33	Childhood cancer survival in Europe and the United States. Cancer, 2002, 95, 1767-1772.	2.0	231
34	Carcinoid Tumors of the Gastrointestinal Tract: Trends in Incidence in England Since 1971. American Journal of Gastroenterology, 2010, 105, 2563-2569.	0.2	229
35	The cancer survival gap between elderly and middle-aged patients in Europe is widening. European Journal of Cancer, 2009, 45, 1006-1016.	1.3	186
36	Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. British Journal of Cancer, 2013, 108, 1195-1208.	2.9	181

3

#	Article	IF	CITATIONS
37	Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncology, The, 2020, 21, e185-e224.	5.1	177
38	Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. British Journal of Cancer, 2010, 103, 446-453.	2.9	171
39	Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology, 2012, 127, 75-82.	0.6	165
40	Cancer prevalence in European registry areas. Annals of Oncology, 2002, 13, 840-865.	0.6	164
41	Breast carcinoma survival in Europe and the United States. Cancer, 2004, 100, 715-722.	2.0	163
42	Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000–2007. Acta Oncológica, 2013, 52, 919-932.	0.8	163
43	Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 2012, 48, 3257-3266.	1.3	158
44	Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncology, The, 2009, 10, 351-369.	5.1	156
45	A Review of Epidemiological Studies of the Health Effects of Living Near or Working with Electricity Generation and Transmission Equipment. International Journal of Epidemiology, 1988, 17, 1-13.	0.9	150
46	What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?. British Journal of Cancer, 2009, 101, S115-S124.	2.9	148
47	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89†828 children from 198 registries in 53 countries. Lancet Haematology,the, 2017, 4, e202-e217.	2.2	141
48	Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: Results from EUROCARE-5. European Journal of Cancer, 2015, 51, 2144-2157.	1.3	138
49	Variation in survival of patients with lung cancer in Europe, 1985–1989. European Journal of Cancer, 1998, 34, 2191-2196.	1.3	135
50	The prognostic role of gender in survival of adult cancer patients. European Journal of Cancer, 1998, 34, 2271-2278.	1.3	135
51	Cancer survival increases in Europe, but international differences remain wide. European Journal of Cancer, 2001, 37, 1659-1667.	1.3	135
52	Cancer Survival in Kentucky and Health Insurance Coverage. Archives of Internal Medicine, 2003, 163, 2135.	4.3	135
53	Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer, 1998, 34, 2176-2183.	1.3	133
54	Survival trends in European cancer patients diagnosed from 1988 to 1999. European Journal of Cancer, 2009, 45, 1042-1066.	1.3	133

#	Article	IF	CITATIONS
55	Incidence and survival of rare urogenital cancers in Europe. European Journal of Cancer, 2012, 48, 456-464.	1.3	132
56	Toward a comparison of survival in American and European cancer patients. Cancer, 2000, 89, 893-900.	2.0	129
57	Deprivation, stage at diagnosis and cancer survival. International Journal of Cancer, 1995, 63, 324-329.	2.3	127
58	Leukaemia and residence near electricity transmission equipment: a case-control study. British Journal of Cancer, 1989, 60, 793-798.	2.9	123
59	Comparative cancer survival information in Europe. European Journal of Cancer, 2009, 45, 901-908.	1.3	123
60	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. American Journal of Gastroenterology, 2007, 102, 1661-1670.	0.2	121
61	Survival from rare cancer in adults: a population-based study. Lancet Oncology, The, 2006, 7, 132-140.	5.1	120
62	The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. European Journal of Cancer, 2009, 45, 909-930.	1.3	120
63	Childhood cancer survival in Europe. Annals of Oncology, 2003, 14, v119-v127.	0.6	119
64	Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet, The, 2014, 383, 564-573.	6.3	118
65	Geographical variation in life expectancy at birth in England and Wales is largely explained by deprivation. Journal of Epidemiology and Community Health, 2005, 59, 115-120.	2.0	115
66	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5. European Journal of Cancer, 2015, 51, 2169-2178.	1.3	115
67	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut, 2005, 54, 268-273.	6.1	114
68	Choice of geographic unit influences socioeconomic inequalities in breast cancer survival. British Journal of Cancer, 2005, 92, 1279-1282.	2.9	114
69	Cancer incidence, survival and mortality: Explaining the concepts. International Journal of Cancer, 2014, 135, 1774-1782.	2.3	114
70	Survival of patients with oesophageal and gastric cancers in Europe. European Journal of Cancer, 1998, 34, 2167-2175.	1.3	110
71	Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study. Gastroenterology, 2007, 132, 899-904.	0.6	109
72	Multiple tumours in survival estimates. European Journal of Cancer, 2009, 45, 1080-1094.	1.3	109

#	Article	IF	CITATIONS
73	Oesophageal cancer survival in Europe: A EUROCARE-4 study. Cancer Epidemiology, 2012, 36, 505-512.	0.8	108
74	Comparability of stage data in cancer registries in six countries: Lessons from the International Cancer Benchmarking Partnership. International Journal of Cancer, 2013, 132, 676-685.	2.3	108
75	Colon cancer survival in the United States by race and stage (2001â€2009): Findings from the CONCORDâ€2 study. Cancer, 2017, 123, 5014-5036.	2.0	108
76	Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. European Journal of Cancer, 2003, 39, 2214-2222.	1.3	107
77	Socioeconomic inequalities in cancer survival in England and Wales. Cancer, 2001, 91, 208-216.	2.0	106
78	Cancer survival in England and Wales at the end of the 20th century. British Journal of Cancer, 2008, 99, S2-S10.	2.9	105
79	Second Cancers Following Radiation Treatment for Cervical Cancer. An International Collaboration Among Cancer Registries. Journal of the National Cancer Institute, 1985, , .	3.0	101
80	Cancer screening: Evidence and practice in Europe 2008. European Journal of Cancer, 2008, 44, 1404-1413.	1.3	100
81	Breast cancer survival in the US and Europe: A CONCORD highâ€resolution study. International Journal of Cancer, 2013, 132, 1170-1181.	2.3	100
82	Survival of children with bone sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 760-766.	1.3	99
83	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncology, The, 2019, 20, 74-87.	5.1	98
84	LEUKAEMIA INCIDENCE IN ELECTRICAL WORKERS. Lancet, The, 1983, 321, 982-983.	6.3	97
85	Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes and Control, 2013, 24, 2169-2176.	0.8	97
86	The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
87	Is England closing the international gap in cancer survival?. British Journal of Cancer, 2015, 113, 848-860.	2.9	97
88	Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. European Journal of Cancer, 1998, 34, 2154-2161.	1.3	96
89	Deprivation and survival from breast cancer. British Journal of Cancer, 1995, 72, 738-743.	2.9	93
90	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecologic Oncology, 2017, 144, 396-404.	0.6	93

#	Article	IF	Citations
91	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic Oncology, 2017, 144, 405-413.	0.6	93
92	Coffee consumption and serum aminotransferases in middle-aged Japanese men. Journal of Clinical Epidemiology, 2001, 54, 823-829.	2.4	91
93	Modelling relative survival in the presence of incomplete data: a tutorial. International Journal of Epidemiology, 2010, 39, 118-128.	0.9	91
94	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer, 2013, 49, 2565-2578.	1.3	91
95	Socioeconomic inequalities in cancer survival in England and Wales. Cancer, 2001, 91, 208-216.	2.0	89
96	lodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. International Journal of Cancer, 1996, 65, 13-19.	2.3	88
97	Measuring cancer prevalence in Europe: the EUROPREVAL Project. Annals of Oncology, 2002, 13, 831-839.	0.6	88
98	National survey of British public's views on use of identifiable medical data by the National Cancer Registry. BMJ: British Medical Journal, 2006, 332, 1068-1072.	2.4	88
99	Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncológica, 2012, 51, 441-453.	0.8	88
100	Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based study. BMJ: British Medical Journal, 2018, 360, k764.	2.4	88
101	Long-term survival expectations of cancer patients in Europe in 2000–2002. European Journal of Cancer, 2009, 45, 1028-1041.	1.3	87
102	The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy, 2013, 112, 148-155.	1.4	87
103	Cancer survival in European adolescents and young adults. European Journal of Cancer, 2003, 39, 2600-2610.	1.3	84
104	Trends in thyroid cancer incidence in Sweden, 1958–1981, by histopathologic type. International Journal of Cancer, 1991, 48, 28-33.	2.3	84
105	Socioeconomic inequalities in cancer survival in Scotland 1986–2000. British Journal of Cancer, 2007, 97, 999-1004.	2.9	84
106	Two countries divided by a common language: health systems in the UK and USA. Journal of the Royal Society of Medicine, 2010, 103, 283-287.	1.1	82
107	Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2206-2216.	1.3	82
108	Survival of women with breast cancer in Europe: Variation with age, year of diagnosis and country., 1998, 77, 679-683.		80

#	Article	IF	Citations
109	The cure of cancer: A European perspective. European Journal of Cancer, 2009, 45, 1067-1079.	1.3	80
110	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Annals of Oncology, 2015, 26, 300-306.	0.6	77
111	Explaining gastric cancer survival differences among European countries. International Journal of Cancer, 2004, 109, 737-741.	2.3	75
112	Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. European Journal of Cancer, 2015, 51, 2217-2230.	1.3	75
113	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Annals of Oncology, 2003, 14, v14-v27.	0.6	74
114	Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open, 2013, 3, e003055.	0.8	72
115	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. European Journal of Cancer, 2017, 77, 140-152.	1.3	72
116	Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults. Occupational and Environmental Medicine, 2022, 79, 433-441.	1.3	72
117	How many deaths have been avoided through improvements in cancer survival?. BMJ: British Medical Journal, 2000, 320, 895-898.	2.4	71
118	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. European Journal of Cancer, 2012, 48, 1167-1175.	1.3	71
119	How many deaths would be avoidable if socioeconomic inequalities in cancer survival in England were eliminated? A national population-based study, 1996–2006. European Journal of Cancer, 2012, 48, 270-278.	1.3	69
120	Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. International Journal of Cancer, 2013, 132, 2404-2412.	2.3	69
121	Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	1.3	66
122	Hodgkin disease survival in Europe and the U.S Cancer, 2006, 107, 352-360.	2.0	64
123	Survival of European patients with central nervous system tumors. International Journal of Cancer, 2012, 131, 173-185.	2.3	64
124	Completeness of cancer registration: a new method for routine use. British Journal of Cancer, 2000, 82, 1111-1116.	2.9	63
125	Invasive extramammary Paget's disease and the risk for secondary tumours in Europe. European Journal of Surgical Oncology, 2012, 38, 214-221.	0.5	63
126	Trends in primary cerebral lymphoma. British Journal of Cancer, 1994, 70, 716-718.	2.9	62

#	Article	IF	CITATIONS
127	Childhood melanoma in Europe since 1978. European Journal of Cancer, 2001, 37, 780-784.	1.3	62
128	Improving cancer control in the European Union: Conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. European Journal of Cancer, 2008, 44, 1457-1462.	1.3	62
129	A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis, 1992, 92, 177-185.	0.4	61
130	The EUROCARE II study. European Journal of Cancer, 1998, 34, 2139-2153.	1.3	61
131	The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. Gastroenterology, 1994, 107, 1335-1344.	0.6	57
132	The journey towards a cancer diagnosis: the experiences of people with cancer, their family and carers. European Journal of Cancer Care, 2003, 12, 317-326.	0.7	57
133	Radiation dose and breast cancer risk in patients treated for cancer of the cervix. International Journal of Cancer, 1989, 44, 7-16.	2.3	56
134	Survival of children with soft-tissue sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 767-774.	1.3	56
135	Incidence of and survival from Wilms' tumour in adults in Europe: Data from the EUROCARE study. European Journal of Cancer, 2006, 42, 2363-2368.	1.3	56
136	Rare cancers of the head and neck area in Europe. European Journal of Cancer, 2012, 48, 783-796.	1.3	55
137	Cancer prevalence in Central Europe: the EUROPREVAL Study. Annals of Oncology, 2003, 14, 313-322.	0.6	54
138	Breast cancer, blindness and melatonin. European Journal of Cancer, 1992, 28, 501-503.	1.3	53
139	Coffee Drinking and Serum Gamma-Glutamyltransferase. Annals of Epidemiology, 1999, 9, 325-331.	0.9	53
140	Increasing incidence of childhood leukaemia: a controversy re-examined. British Journal of Cancer, 2007, 97, 1009-1012.	2.9	53
141	Making progress against cancer in Europe in 2008. European Journal of Cancer, 2008, 44, 1451-1456.	1.3	53
142	The state of the art of cancer control in 30 European countries in 2008. International Journal of Cancer, 2010, 126, 2700-2715.	2.3	53
143	Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: A population-based cohort study. British Journal of Cancer, 1987, 56, 349-355.	2.9	52
144	Variations in survival from breast cancer in Europe by age and country, 1978–1989. European Journal of Cancer, 1998, 34, 2204-2211.	1.3	52

#	Article	IF	CITATIONS
145	The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. The Lancet Gastroenterology and Hepatology, 2021, 6, 709-722.	3.7	52
146	Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORDâ€₂ study. Cancer, 2017, 123, 5178-5189.	2.0	49
147	Trends in breast cancer incidence, survival, and mortality. Lancet, The, 2000, 356, 590-591.	6.3	48
148	The impact of life tables adjusted for smoking on the socio-economic difference in net survival for laryngeal and lung cancer. British Journal of Cancer, 2014, 111, 195-202.	2.9	48
149	Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992. European Journal of Cancer, 2001, 37, 711-721.	1.3	47
150	Colorectal cancer survival trends in Norway 1958–1997. European Journal of Cancer, 2004, 40, 734-742.	1.3	46
151	Mortality among male anaesthetists in the United Kingdom, 1957-83 BMJ: British Medical Journal, 1987, 295, 360-362.	2.4	45
152	Survival from Uveal Melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiology, 2007, 14, 3-8.	0.8	44
153	Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973–2004): the potential role of health care. Annals of Oncology, 2011, 22, 1661-1666.	0.6	44
154	The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England. Cancer Epidemiology, 2015, 39, 641-649.	0.8	44
155	Carcinoma of endocrine organs: Results of the RARECARE project. European Journal of Cancer, 2012, 48, 1923-1931.	1.3	43
156	Variation in survival of adult patients with thyroid cancer in Europe. European Journal of Cancer, 1998, 34, 2248-2252.	1.3	42
157	Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995–2002. European Journal of Cancer, 2012, 48, 1417-1424.	1.3	42
158	Confidentiality and the public interest in medical research – will we ever get it right?. Clinical Medicine, 2003, 3, 219-228.	0.8	41
159	Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. BMJ: British Medical Journal, 2011, 342, d3399-d3399.	2.4	41
160	Variation in survival of adult patients with haematological malignancies in Europe since 1978. European Journal of Cancer, 1998, 34, 2253-2263.	1.3	40
161	Embryonal cancers in Europe. European Journal of Cancer, 2012, 48, 1425-1433.	1.3	39
162	Breast cancer survival in South Asian women in England and Wales. Journal of Epidemiology and Community Health, 2005, 59, 402-406.	2.0	38

#	Article	lF	CITATIONS
163	Survival of adult patients with cancer of soft tissues or bone in Europe. European Journal of Cancer, 1998, 34, 2212-2217.	1.3	37
164	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. European Journal of Cancer, 2012, 48, 159-169.	1.3	37
165	Cancer incidence in South Asian migrants to England, 1986–2004: Unraveling ethnic from socioeconomic differentials. International Journal of Cancer, 2013, 132, 1886-1894.	2.3	37
166	Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review. Journal of Global Oncology, 2019, 5, 1-25.	0.5	37
167	No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial. British Journal of Cancer, 2008, 99, 1923-1928.	2.9	36
168	Life Tables for World-Wide Comparison of Relative Survival for Cancer (CONCORD Study). Tumori, 2008, 94, 658-668.	0.6	36
169	Survival after acute lymphocytic leukaemia: effects of socioeconomic status and geographic region. Archives of Disease in Childhood, 1999, 80, 311-317.	1.0	35
170	Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study. Annals of Oncology, 2011, 22, 165-174.	0.6	35
171	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	1.7	35
172	The completeness of cancer registration in England: an assessment from the Oxford-FPA contraceptive study. British Journal of Cancer, 1988, 58, 507-511.	2.9	34
173	Improved survival for patients with testicular cancer in Europe since 1978. European Journal of Cancer, 1998, 34, 2236-2240.	1.3	34
174	Survival rates for primary malignant brain tumours in Europe. European Journal of Cancer, 1998, 34, 2241-2247.	1.3	33
175	Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978–1992. European Journal of Cancer, 2001, 37, 687-694.	1.3	33
176	Geographical variability in survival of European children with central nervous system tumours. European Journal of Cancer, 2017, 82, 137-148.	1.3	33
177	Adult leukemia survival trends in the United States by subtype: A populationâ€based registry study of 370,994 patients diagnosed during 1995â€2009. Cancer, 2018, 124, 3856-3867.	2.0	33
178	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European Journal of Cancer, 2008, 44, 579-587.	1.3	32
179	Survival of childhood lymphomas in Europe, 1978–1992. European Journal of Cancer, 2001, 37, 703-710.	1.3	31
180	Survival from bladder cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S86-S89.	2.9	31

#	Article	IF	Citations
181	Cancer mortality in ethnic South Asian migrants in England and Wales (1993–2003): patterns in the overall population and in first and subsequent generations. British Journal of Cancer, 2010, 102, 1438-1443.	2.9	31
182	Survival for retinoblastoma in Europe. European Journal of Cancer, 2001, 37, 730-735.	1.3	30
183	A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Annals of Oncology, 2002, 13, 1128-1139.	0.6	30
184	Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. International Journal of Cancer, 2003, 103, 538-543.	2.3	30
185	Survival from cancer of the larynx in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S35-S37.	2.9	30
186	†Cure†M from breast cancer among two populations of women followed for 23 years after diagnosis. Annals of Oncology, 2009, 20, 1331-1336.	0.6	30
187	The effect of multiple primary rules on cancer incidence rates and trends. Cancer Causes and Control, 2016, 27, 377-390.	0.8	30
188	Carcinogenicity evaluations and ongoing studies: the IARC databases Environmental Health Perspectives, 1991, 96, 5-9.	2.8	29
189	Trends in cervical cancer survival in Europe, 1983–1994: A population-based study. Gynecologic Oncology, 2007, 105, 609-619.	0.6	29
190	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: AÂEUROCARE-5 study. European Journal of Cancer, 2017, 84, 335-353.	1.3	29
191	Electronic availability of EUROCARE-3 data: a tool for further analysis. Annals of Oncology, 2003, 14, v150-v155.	0.6	28
192	Survival from cancer of the breast in women in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S53-S55.	2.9	28
193	Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods. BMC Cancer, 2017, 17, 159.	1.1	28
194	Colorectal cancer incidence among young adults in England: Trends by anatomical sub-site and deprivation. PLoS ONE, 2019, 14, e0225547.	1.1	28
195	Variation in survival for adults with Nasopharyngeal cancer in Europe, 1978–1989. European Journal of Cancer, 1998, 34, 2162-2166.	1.3	27
196	Populationâ€based cancer survival in the United States: Data, quality control, and statistical methods. Cancer, 2017, 123, 4982-4993.	2.0	27
197	Survival from rectal and anal cancers in England and Wales, 1986–2001. European Journal of Cancer, 2006, 42, 1434-1440.	1.3	26
198	Survival from cancer of the pancreas in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S21-S23.	2.9	26

#	Article	IF	Citations
199	Survival from cancer of the lung in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S40-S42.	2.9	26
200	Pattern of symptoms and signs of primary intracranial tumours in children and young adults: a record linkage study. Archives of Disease in Childhood, 2015, 100, 1115-1122.	1.0	26
201	Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study. Tumori, 2017, 103, 22-32.	0.6	26
202	Survival from cancer of the rectum in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S30-S32.	2.9	25
203	Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer, 2008, 99, 598-S101.	2.9	24
204	Would compliance with cancer care standards improve survival for breast, colorectal and lung cancers?. Journal of Epidemiology and Community Health, 2008, 62, 650-654.	2.0	24
205	Health Systems Performance and Cancer Outcomes. Journal of the National Cancer Institute Monographs, 2013, 2013, 7-12.	0.9	24
206	Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. The Lancet Child and Adolescent Health, 2022, 6, 409-431.	2.7	24
207	Extremely low-frequency electric and magnetic fields and risk of human cancer. Bioelectromagnetics, 1990, 11, 91-99.	0.9	23
208	Cancer control in Europe: A proposed set of European Cancer Health Indicators. European Journal of Public Health, 2003, 13, 116-119.	0.1	23
209	Childhood leukaemia: long-term excess mortality and the proportion †cured'. British Journal of Cancer, 2008, 99, 219-223.	2.9	23
210	Geographical variation in cancer survival in England, 1991-2006: an analysis by Cancer Network. Journal of Epidemiology and Community Health, 2011, 65, 1044-1052.	2.0	23
211	Trends and inequalities in laryngeal cancer survival in men and women: England and Wales 1991–2006. Oral Oncology, 2012, 48, 284-289.	0.8	23
212	Cancer survival differences between South Asians and non-South Asians of England in 1986–2004, accounting for age at diagnosis and deprivation. British Journal of Cancer, 2015, 113, 173-181.	2.9	23
213	Rectal cancer survival in the United States by race and stage, 2001 to 2009: Findings from the CONCORDâ€2 study. Cancer, 2017, 123, 5037-5058.	2.0	23
214	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Annals of Oncology, 2004, 15, 1136-1142.	0.6	22
215	Funnel plots for population-based cancer survival: principles, methods and applications. Statistics in Medicine, 2014, 33, 1070-1080.	0.8	22
216	Control of data quality for population-based cancer survival analysis. Cancer Epidemiology, 2014, 38, 314-320.	0.8	22

#	Article	IF	CITATIONS
217	Variations in survival for invasive cervical cancer among European women, 1978-89. EUROCARE Working Group. Cancer Causes and Control, 1999, 10, 575-581.	0.8	21
218	Survival from prostate cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S75-S77.	2.9	21
219	War on cancer and the influence of the medical-industrial complex. Journal of Cancer Policy, 2013, 1, e31-e34.	0.6	21
220	Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (<scp>UK</scp>) and New South Wales (Australia): Women diagnosed 1997–2006. International Journal of Cancer, 2016, 138, 2396-2403.	2.3	21
221	Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013. BMC Cancer, 2018, 18, 492.	1.1	21
222	The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). Neuro-Oncology, 2021, 23, 1765-1776.	0.6	21
223	Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori, 2008, 94, 658-68.	0.6	21
224	Cancer registration in the European Community. International Journal of Cancer, 1988, 42, 339-345.	2.3	20
225	Improving survival of melanoma patients in Europe since 1978. European Journal of Cancer, 1998, 34, 2197-2203.	1.3	20
226	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988–2011: a populationâ€based study. British Journal of Haematology, 2016, 173, 292-302.	1,2	20
227	Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S24-S31.	0.6	20
228	Survival from cancer of the colon in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S26-S29.	2.9	19
229	Does the timing of comorbidity affect colorectal cancer survival? A population based study. Postgraduate Medical Journal, 2010, 86, 73-78.	0.9	19
230	Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme. Cancer, 2017, 123, 4977-4981.	2.0	19
231	Cancer prevalence in Northern Europe: the EUROPREVAL study. Annals of Oncology, 2003, 14, 946-957.	0.6	18
232	Survival from testicular cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S80-S82.	2.9	18
233	Large differences in patterns of breast cancer survival between Australia and England: A comparative study using cancer registry data. International Journal of Cancer, 2009, 124, 2391-2399.	2.3	18
234	Populationâ€based cancer survival (2001 to 2009) in the United States: Findings from the CONCORDâ€2 study. Cancer, 2017, 123, 4963-4968.	2.0	18

#	Article	IF	Citations
235	The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival. Journal of Global Oncology, 2019, 5, 1-9.	0.5	18
236	Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study. Pancreatology, 2020, 20, 454-461.	0.5	18
237	Confidentiality in the cancer registry. British Journal of Cancer, 1992, 66, 1138-1149.	2.9	17
238	Opinion: why the variation in breast cancer survival in Europe?. Breast Cancer Research, 1999, 1, 22-6.	2.2	17
239	Predicted trends in long-term breast cancer survival in England and Wales. British Journal of Cancer, 2007, 96, 1135-1138.	2.9	17
240	Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3). British Journal of Dermatology, 2022, 187, 364-380.	1.4	17
241	Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978. European Journal of Cancer, 2001, 37, 695-702.	1.3	16
242	Survival from cancer of the uterus in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S65-S67.	2.9	16
243	Survival from cancer of the ovary in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S70-S72.	2.9	16
244	Cancer control-planning and monitoring population-based systems. Tumori, 2009, 95, 568-578.	0.6	16
245	Harmonization may be counterproductiveat least for parts of Europe where public health research operates effectively. European Journal of Public Health, 2011, 21, 686-687.	0.1	16
246	Cancer Survival Trends in Osaka, Japan: the Influence of Age and Stage at Diagnosis. Japanese Journal of Clinical Oncology, 2007, 37, 452-458.	0.6	15
247	Comparative indicators for cancer network management in England: Availability, characteristics and presentation. BMC Health Services Research, 2008, 8, 45.	0.9	15
248	Full dates (day, month, year) should be used in populationâ€based cancer survival studies. International Journal of Cancer, 2012, 131, E1120-4.	2.3	15
249	Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S63-S69.	0.6	15
250	Excess mortality among essential workers in England and Wales during the COVID-19 pandemic. Journal of Epidemiology and Community Health, 2022, 76, 660-666.	2.0	15
251	Cancer risks related to electricity production. European Journal of Cancer & Clinical Oncology, 1991, 27, 1504-1519.	0.9	14
252	International association between Helicobacter pylori and gastric cancer. Lancet, The, 1993, 342, 120-121.	6.3	14

#	Article	IF	Citations
253	Survival of children with Wilms' tumour in Europe. European Journal of Cancer, 2001, 37, 736-743.	1.3	14
254	Survival from cancer of the oesophagus in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S11-S13.	2.9	14
255	No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. British Journal of Cancer, 2014, 111, 589-597.	2.9	14
256	Cancer: the elephant in the room. Lancet, The, 2015, 385, 1047-1048.	6.3	14
257	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S48-S55.	0.6	14
258	Which indicators of early cancer diagnosis from population-based data sources are associated with short-term mortality and survival?. Cancer Epidemiology, 2018, 56, 161-170.	0.8	14
259	Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records. BMJ: British Medical Journal, 2000, 320, 145-147.	2.4	13
260	Survival of children with thyroid cancer in Europe 1978–1989. European Journal of Cancer, 2001, 37, 775-779.	1.3	13
261	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S77-S84.	0.6	13
262	Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3). Gynecologic Oncology, 2021, 163, 305-311.	0.6	13
263	The completeness of cancer registration in follow-up studies $\hat{a}\in$ A cautionary note. British Journal of Cancer, 1987, 56, 357-359.	2.9	12
264	Regional differences in populationâ€based cancer survival between six prefectures in Japan: Application of relative survival models with funnel plots. Cancer Science, 2009, 100, 1306-1311.	1.7	12
265	Cancer survival in the developing world. Lancet Oncology, The, 2010, 11, 110-111.	5.1	12
266	lodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type., 1996, 65, 13.		12
267	Survival from melanoma of the skin in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S47-S49.	2.9	11
268	Survival from multiple myeloma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, \$110-\$112.	2.9	11
269	International collaborations in cancer control and the Third International Cancer Control Congress. Tumori, 2009, 95, 579-596.	0.6	11
270	Socio-economic inequalities in testicular cancer survival within two clinical studies. Cancer Epidemiology, 2012, 36, 217-221.	0.8	11

#	Article	IF	CITATIONS
271	Trends in cancer survival in Spearhead Primary Care Trusts in England,1998–2004. Health Statistics Quarterly, 2009, 41, 7-12.	0.9	10
272	How many cancer deaths could New Zealand avoid if fiveâ€year relative survival ratios were the same as in Australia?. Australian and New Zealand Journal of Public Health, 2015, 39, 157-161.	0.8	10
273	Adjusting for overdispersion in piecewise exponential regression models to estimate excess mortality rate in population-based research. BMC Medical Research Methodology, 2016, 16, 129.	1.4	10
274	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S107-S113.	0.6	10
275	Where are the opportunities for an earlier diagnosis of primary intracranial tumours in children and young adults?. European Journal of Paediatric Neurology, 2017, 21, 388-395.	0.7	10
276	The role of cancer registries. Clinical Oncology, 1995, 7, 143-144.	0.6	9
277	Improvement in survival of patients with cancer of the kidney in Europe. European Journal of Cancer, 1998, 34, 2232-2235.	1.3	9
278	Guidelines for confidentiality and cancer registration. British Journal of Cancer, 2005, 92, 2095-2096.	2.9	9
279	Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1–75). Annals of Oncology, 2007, 18, 1433-1435.	0.6	9
280	Is the performance of cancer services influenced more by hospital factors or by specialization?. Journal of Public Health, 2008, 30, 69-74.	1.0	9
281	Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S70-S76.	0.6	9
282	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S85-S91.	0.6	9
283	Ethnic, racial and socioeconomic disparities in breast cancer survival in two Brazilian capitals between 1996 and 2012. Cancer Epidemiology, 2021, 75, 102048.	0.8	9
284	Extremely low frequency (ELF) electromagnetic fields and leukaemia in children. British Journal of Cancer, 1990, 62, 331-332.	2.9	8
285	Obesity and ovarian cancer. European Journal of Cancer, 1997, 33, 1529-1531.	1.3	8
286	Cancer information under threat: The case for legislation. Annals of Oncology, 2001, 12, 145-147.	0.6	8
287	Guidelines on confidentiality for population-based cancer registration. European Journal of Cancer Prevention, 2005, 14, 309-327.	0.6	8
288	Survival from non-Hodgkin lymphoma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S104-S106.	2.9	8

#	Article	IF	CITATIONS
289	Are international differences in breast cancer survival between ⟨scp⟩A⟨lscp⟩ustralia and the UK present amongst both screenâ€detected women and nonâ€screenâ€detected women? survival estimates for women diagnosed in ⟨scp⟩W⟨lscp⟩est ⟨scp⟩M⟨lscp⟩idlands and ⟨scp⟩N⟨lscp⟩ew ⟨scp⟩S⟨lscp⟩outh ⟨scp⟩W⟨lscp⟩ales 1997–2006. International lournal of Cancer, 2016, 138, 2404-2414.	2.3	8
290	Do cancer survival statistics for every hospital make sense?. Lancet Oncology, The, 2016, 17, 1192-1194.	5.1	8
291	Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). JNCI Cancer Spectrum, 2020, 4, pkaa078.	1.4	8
292	Survival and reduction in mortality from breast cancer. BMJ: British Medical Journal, 2000, 321, 1470-1470.	2.4	8
293	A Plague Epidemic in Voluntary Quarantine. International Journal of Epidemiology, 1986, 15, 379-385.	0.9	7
294	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. European Journal of Cancer Prevention, 2017, 26, S9-S15.	0.6	7
295	Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S40-S47.	0.6	7
296	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S16-S23.	0.6	7
297	Are socio-economic inequalities in breast cancer survival explained by peri-diagnostic factors?. BMC Cancer, 2021, 21, 485.	1.1	7
298	Space-time clustering of nasopharyngeal carcinoma in Greenland Eskimos. British Journal of Cancer, 1985, 52, 909-914.	2.9	6
299	Cancer incidence in Murcia, Spain, in 1982: First results from a population-based cancer registry. International Journal of Cancer, 1986, 38, 1-7.	2.3	6
300	Hormone-Replacement Therapy and Heart Disease. New England Journal of Medicine, 1987, 316, 1274-1275.	13.9	6
301	Act now against new NHS competition regulations. BMJ, The, 2013, 346, f1819-f1819.	3.0	6
302	Cancer survival: the CONCORD-2 study – Authors' reply. Lancet, The, 2015, 386, 429-430.	6.3	6
303	Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study. British Journal of Cancer, 2006, 95, 1296-1300.	2.9	5
304	Survival from cancers of the kidney and ureter in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S93-S95.	2.9	5
305	Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980–2002. Australian and New Zealand Journal of Public Health, 2010, 34, 206-213.	0.8	5
306	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S92-S99.	0.6	5

#	Article	IF	CITATIONS
307	Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009–2013? Implications for use of the data in research. British Journal of Cancer, 2018, 118, 733-737.	2.9	5
308	Global Trends in Survival From Astrocytic Tumors in Adolescents and Young Adults: A Systematic Review. JNCI Cancer Spectrum, 2020, 4, pkaa049.	1.4	5
309	Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin's Lymphoma Diagnosed in England and Wales between 1986 and 1999 Blood, 2005, 106, 749-749.	0.6	5
310	LEUKAEMIA MORTALITY IN AMATEUR RADIO OPERATORS. Lancet, The, 1985, 326, 106-107.	6.3	4
311	Cancer mortality in rio de janeiro. International Journal of Cancer, 1990, 46, 173-177.	2.3	4
312	Cancer and electromagnetic fields. Lancet, The, 1990, 336, 1259.	6.3	4
313	Survival of children with liver tumours in Europe 1978–1989. European Journal of Cancer, 2001, 37, 744-749.	1.3	4
314	Survival from cancer of the stomach in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S16-S18.	2.9	4
315	Survival from cancer of the uterine cervix in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S59-S62.	2.9	4
316	Leukaemia survival trends in children with Down's syndrome in Great Britain, 1971-2000: a population-based study. Journal of Epidemiology and Community Health, 2010, 64, 604-609.	2.0	4
317	Commentary: Estimating cancer survival—which is the right approach?. International Journal of Epidemiology, 2010, 39, 611-612.	0.9	4
318	Rebuttal to editorial saying cancer survival statistics are misleading. BMJ: British Medical Journal, 2011, 343, d4214-d4214.	2.4	4
319	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S114-S120.	0.6	4
320	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S32-S39.	0.6	4
321	TAMOXIFEN PROPHYLAXIS. Lancet, The, 1986, 327, 263-265.	6.3	3
322	Mortality from dementias and neurodegenerative disorders in people aged 15-64Âin England and Wales in 1979-96. BMJ: British Medical Journal, 1998, 317, 320-321.	2.4	3
323	Survival from adult leukaemia in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S116-S118.	2.9	3
324	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK – Authors' reply. Lancet, The, 2011, 377, 1149-1150.	6.3	3

#	Article	IF	CITATIONS
325	Letter from America. Lancet, The, 2012, 379, 1288.	6.3	3
326	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S56-S62.	0.6	3
327	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S121-S127.	0.6	3
328	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. European Journal of Cancer Prevention, 2017, 26, S3-S8.	0.6	3
329	Fleshing out the data: when epidemiological researchers engage with patients and carers. Learning lessons from a patient involvement activity. BMJ Open, 2020, 10, e036311.	0.8	3
330	World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000–2014 (CONCORD-3). Cancer Epidemiology, 2022, 80, 102196.	0.8	3
331	Safety of tamoxifen. Lancet, The, 1996, 347, 836-837.	6.3	2
332	Commentary: Is epidemiology really dead, anyway? * A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950 2000 AD'. International Journal of Epidemiology, 2007, 36, 719-723.	0.9	2
333	Survival from twenty adult cancers in the UK and Republic of Ireland in the late twentieth century. Health Statistics Quarterly, 2010, 46, 7-26.	0.9	2
334	Lung cancer in young women remains rare. Lung Cancer, 2010, 67, 124-125.	0.9	2
335	Conference report: improving outcomes for gastrointestinal cancer in the UK. Frontline Gastroenterology, 2018, 9, 49-61.	0.9	2
336	How Do Biological Characteristics of Primary Intracranial Tumors Affect Their Clinical Presentation in Children and Young Adults?. Journal of Child Neurology, 2018, 33, 503-511.	0.7	2
337	Cancer survival indicators by Cancer Network: a methodological perspective. Health Statistics Quarterly, 2007, , 36-41.	0.9	2
338	Cancer survival trends in Kuwait, 2000-2013: A population-based study. gulf journal of oncology, The, 2019, 1, 39-52.	0.2	2
339	Survival from five common cancers in Georgia, 2015–2019 (CONCORD). Cancer Epidemiology, 2022, 79, 102190.	0.8	2
340	DUAL MEANING OF MEMBERSHIP. Lancet, The, 1987, 330, 265.	6.3	1
341	Bradford NHS Trust and Panorama. Lancet, The, 2006, 368, 730-731.	6.3	1
342	Reed Elsevier and the arms trade revisited. Lancet, The, 2007, 369, 987.	6.3	1

#	Article	IF	CITATIONS
343	Reply to investigating changes over time in socioeconomic gaps in cancer survival: does choice of approach matter?. Annals of Oncology, 2012, 23, 279-280.	0.6	1
344	Optimal use of staging data in international comparisons of colorectal cancer survival. Acta $Oncol\tilde{A}^3$ gica, 2014, 53, 847-848.	0.8	1
345	Reply to comments by Dr. Frisch and Dr. Van Howe. Cancer Causes and Control, 2014, 25, 407-408.	0.8	1
346	Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): Impact of morphology. Annals of Oncology, 2018, 29, viii125.	0.6	1
347	Reply to Colon cancer survival in the US Department of Veterans Affairs by race and stage: 2001 through 2009. Cancer, 2018, 124, 2859-2860.	2.0	1
348	Social Disparities in Survival from Breast Cancer in Europe. , 2021, , 71-111.		1
349	A Novel Approach to Obtain Follow-up Data on the Vital Status of Registered Cancer Patients: The Kuwait Cancer Registry Experience. gulf journal of oncology, The, 2019, 1, 31-38.	0.2	1
350	EPIDEMIOLOGY AND THE CLINICIAN. Lancet, The, 1981, 318, 640-641.	6.3	0
351	CIGARETTE ADVERTISING. Lancet, The, 1982, 320, 1106.	6.3	0
352	Multiple primary malignancy in England and Wales, 1971–80: a pilot study of OPCS records. Journal of Public Health, 1987, 9, 15-24.	1.0	0
353	Analysis of leukaemia registration. Journal of Public Health, 1988, 10, 73-74.	1.0	0
354	Letter to mutation epidemiologists. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1989, 216, 91.	0.4	0
355	Journal of clinical epidemiology 1988; 41: 517–518. Journal of Clinical Epidemiology, 1989, 42, 480.	2.4	0
356	National scientific medical meeting 1997 abstracts. Irish Journal of Medical Science, 1998, 167, 1-44.	0.8	0
357	Inequalities in cancer survival: Spearhead Primary Care Trusts are appropriate geographic units of analyses. Health Statistics Quarterly, 2010, 48, 81-90.	0.9	0
358	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S100-S106.	0.6	0
359	Reply to correspondence "Do big numbers assure high-quality of data?― Lancet Haematology,the, 2017, 4, e410.	2.2	0
360	Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): Preliminary findings and plans for further research. Annals of Oncology, 2018, 29, viii574.	0.6	0

ARTICLE IF CITATIONS

361 Disparities in Cancer Survival in Adults in Europe: The CONCORD Programme., 2021,, 159-178.